biotech · Acute Myeloid Leukemia · Acute Myelogenous Leukemia in Relapse · APTOF
Aptose Biosciences
Aptose Biosciences patent portfolio — 7 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2014
- Employees
- 32
- Programs
- 8
- Drugs
- 1
- Patents
- 7
Aptose Biosciences patents
7 pharmaceutical patents indexed for Aptose Biosciences. 0 expire within 24 months.
Aptose Biosciences has 7 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 11279703
Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof
granted -
US 11149047
Aryl imidazoles for treatment of cancer
granted -
US 11104957
Compositions and methods for treating cancers
granted -
US 10080739
Aryl imidazoles and their use as anti-cancer agents
granted -
US 9567643
Compositions and methods for treating cancers
granted -
US 8987305
2,4,5-trisubstituted imidazoles and their use as anti-microbial agents
granted -
US 8969372
Aryl imidazoles and their use as anti-cancer agents
granted
Frequently asked questions
How many patents does Aptose Biosciences have?
7 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Aptose Biosciences patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.